Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: Pain. 2017 Sep;158(9):1711–1722. doi: 10.1097/j.pain.0000000000000966

Figure 7.

Figure 7

A: URB597 decreased withdrawal response frequency in hyperalgesic HbSS-BERK sickle mice. Intraplantar administration of 10 μg URB597 decreased mean (±SEM) paw withdrawal frequency at 30, 60, 90, and 120 min after injection. This effect was blocked by pretreatment with the CB1 receptor antagonist AM281 but not the CB2 receptor antagonist AM630, and response frequencies decreased at 30, 60, 90, and 120 min post-injection. *p<.05, **p<.01, ***p<.001 vs. vehicle-treated group. #p<.05, ##p<.01, ###p<.001 indicates significant differences from pre-injection.

B: Intraplantar administration of URB597 decreased paw withdrawal frequency in hyperalgesic HbSS-BERK/CBR2−/− mice. URB597 decreased paw withdrawal frequency at 30, 60, and 90 min after administration in sickle mice lacking CB2 receptors. *p<.05, **p<.01, ***p<.001 vs. vehicle-treated group. ##p<.01, ###p<.001 indicates significant differences from pre-injection.